Kinetics of Wound Development and Healing Suggests a Skin-Stabilizing Effect of Allogeneic ABCB5+ Mesenchymal Stromal Cell Treatment in Recessive Dystrophic Epidermolysis Bullosa
Cells · 2023
DOI: 10.3390/cells12111468 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2023. Verfasst von Elke Niebergall-Roth und 8 weiteren Autor:innen. Beteiligte Einrichtung: RHEACELL GmbH & Co. KG, 69120 Heidelberg, Germany. Hauptthemen laut MEDLINE: Epidermolysis Bullosa Dystrophica, Mesenchymal Stem Cells, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIA NIH HHS, NEI NIH HHS.
Abstract (Originalsprache)
Recessive dystrophic epidermolysis (RDEB) is a rare, inherited, and currently incurable skin blistering disorder characterized by cyclically recurring wounds coexisting with chronic non-healing wounds. In a recent clinical trial, three intravenous infusions of skin-derived ABCB5+ mesenchymal stromal cells (MSCs) to 14 patients with RDEB improved the healing of wounds that were present at baseline. Since in RDEB even minor mechanical forces perpetually provoke the development of new or recurrent wounds, a post-hoc analysis of patient photographs was performed to specifically assess the effects of ABCB5+ MSCs on new or recurrent wounds by evaluating 174 wounds that occurred after baseline. During 12 weeks of systemic treatment with ABCB5+ MSCs, the number of newly occurring wounds declined. When compared to the previously reported healing responses of the wounds present at baseline, the newly occurring wounds healed faster, and a greater portion of healed wounds remained stably closed. These data suggest a previously undescribed skin-stabilizing effect of treatment with ABCB5+ MSCs and support repeated dosing of ABCB5+ MSCs in RDEB to continuously slow the wound development and accelerate the healing of new or recurrent wounds before they become infected or progress to a chronic, difficult-to-heal stage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- RHEACELL GmbH & Co. KG, 69120 Heidelberg, Germany.
- Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
- Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA.
- Transplant Research Program, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
- School of Medical and Health Sciences, Edith Cowan University, Perth 6027, Australia.
ORCID-Profile: Elke Niebergall-Roth, Markus H Frank
Förderung
- NHLBI NIH HHS
- NIA NIH HHS
- NEI NIH HHS
- National Institutes of Health (NIH), National Eye Institute (NEI)
- National Heart, Lung, and Blood Institute
- National Institute on Aging
Zitieren
APA
Niebergall-Roth, E., Dieter, K., Daniele, C., Fluhr, S., Khokhrina, M., Silva, I., Ganss, C., Frank, M. H., & Kluth, M. A. (2023). Kinetics of Wound Development and Healing Suggests a Skin-Stabilizing Effect of Allogeneic ABCB5+ Mesenchymal Stromal Cell Treatment in Recessive Dystrophic Epidermolysis Bullosa. Cells. https://doi.org/10.3390/cells12111468
Vancouver
Niebergall-Roth E, Dieter K, Daniele C, Fluhr S, Khokhrina M, Silva I, et al. Kinetics of Wound Development and Healing Suggests a Skin-Stabilizing Effect of Allogeneic ABCB5+ Mesenchymal Stromal Cell Treatment in Recessive Dystrophic Epidermolysis Bullosa. Cells. 2023. doi:10.3390/cells12111468
BibTeX
@article{NiebergallRoth2023,
author = {Niebergall-Roth, Elke and Dieter, Kathrin and Daniele, Cristina and Fluhr, Silvia and Khokhrina, Maria and Silva, Ines and Ganss, Christoph and Frank, Markus H and Kluth, Mark A},
title = {Kinetics of Wound Development and Healing Suggests a Skin-Stabilizing Effect of Allogeneic ABCB5+ Mesenchymal Stromal Cell Treatment in Recessive Dystrophic Epidermolysis Bullosa},
journal = {Cells},
year = {2023},
doi = {10.3390/cells12111468}
}
EUVIMED